EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY

Giant cell arteritis (GCA), formerly known as Horton's disease, is among the most common diseases from a group of systemic vasculitides; its clinical significance is complemented with the potential involvement of the coronary arteries, aorta, and cranial arteries with development of ischemic optic neuropathy if there is no timely treatment that results in rapid and irreversible visual loss. The elderly age of patients is one of the key aspects of GCA. Therefore, the disease is often accompanied by various comorbidities that have considerable impact on the choice of a treatment regimen and limit the use of standard therapy with glucocorticoids (GCs). The complications due to GC treatment can be competitive in severity with GCA, especially in elderly multimorbid patients. Progress in rheumatology due to the introduction of biological agents (BAs) has created the preconditions for the development of a new area of pharmacotherapy for GCA associated with interleukin 6 (IL6) inhibition using tocilizumab (TCZ). According to the results of two randomized placebocontrolled trials (RPCTs), which were published in 2016, the rate of remission with TCZ treatment was significantly higher in patients with GCA than that in the placebo group (p = 0.03–0.0001), as is relapse-free survival after 52 weeks of TCZ treatment (85 and 20%, respectively; p ≤ 0.001), the incidence of serious adverse events (AE) was 14–35%. In 2017, the results of Phase III GiACTA RPCT became the basis for approval of the use of TCZ for the treatment of GCA in the United States and Europe. The authors present their own results of a small prospective study of TCZ in 7 patients with active GCA with severe comorbidity, including multimorbidity, that potentially increases the risk for AE due to GC therapy. The mean age of the patients was 71.3±7.6 years; among them there was one man and 6 women. The administration of TCZ in a monthly dose of 2.3–8.8 mg/kg for 1–10 months with a cumulative dose of 10–58.1 mg/kg could reduce the mean daily dose of prednisolone to 15 (5–32.5) mg, thereby preventing the development or progression of AE, and all the 7 patients could rather rapidly achieve GCA remission. A recurrence after therapy discontinuation was noted in one patient. TCZ treatment was accompanied by serious AE (purulent elbow bursitis); and other two patients had AE a few months after TCZ discontinuation. There were no fatal outcomes. Thus, the presented results suggest that the use of IL6 inhibitors in patients with GCA, including those with severe comorbidity, can be regarded as a potentially effective innovative (off-label) treatment strategy with an acceptable safety profile. The further expansion of an evidence base and the clarification of the medical and economic aspects of TCZ treatment in some groups of GCA will help justify the choice of BAs.

giant cell arteritis, interleukin 6, tocilizumab

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715

2. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-8. doi: 10.1002/art.1780330810

3. Dejaco C, Singh YP, Perel P, et al; European League Against Rheumatism; American College of Rheumatology. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2015;67(10):2569-80. doi: 10.1002/art.39333

4. Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore). 1999;78(5):292-308. doi: 10.1097/00005792-199909000-00002

5. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):6339. doi: 10.1002/art.30155

6. Saleh M, Turesson C, Englund M, et al. Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Populationbased Study. J Rheumatol. 2016;43(8):1559-65. doi: 10.3899/jrheum.151033

7. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Int Med. 1994;121:484-91. doi: 10.7326/0003-4819-121-7199410010-00003

8. Emilie D, Liozon E, Crevon MC, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39:172. doi: 10.1016/0198-8859(94)90096-5

9. Salvarani C, Cantini F, Boiardi L, Hunder G. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exper Rheumatol. 2003;21(6 Suppl 32):23-8.

10. Pulsatelli L, Boiardi L, Assirelli E, et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol. 2017;35 Suppl 103(1):102-10.

11. Van der Geest KS, Abdulahad WH, Rutgers A, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology. 2015;54:1397-402. doi: 10.1093/rheumatology/keu526

12. Miyabe C, Miyabe Y, Strle K, et al. An expanded population of pathogenic regulatoty T cells in giant cell arteitis is abrogayed by IL-6 blockade therapy. Ann Rheum Dis. 2016. doi: 10.1136/annrheumdis-2016-210070

13. Villiger P, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921-7. doi: 10.1016/S0140-6736(16)00560-2

14. Tuckwell K, Collinson N, Dimonaco S, et al. GiACTA Investigators. Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Semin Arthritis Rheum. 2016 Nov 15. pii: S0049-0172(16)30275-X. doi: 10.1016/j.semarthrit.2016.11.002

15. Stone JH, Tuckwell K, Dimonaco S, et al. Efficacy and safety of tocilizumab in patients with giant cell arteritis: Primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2016;68 Suppl 10:abstr.911.

16. Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep. 2011;2011. pii: bcr0420114135. doi: 10.1136/bcr.04.2011.4135

17. Сатыбалдыев АМ, Сатыбалдыева МА, Насонов ЕЛ. Тоцилизумаб в лечении ревматической полимиалгии и гигантоклеточного артериита. Клиническая фармакология и терапия. 2017;(1):47-53.

18. Kermani TA, Schäfer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010;69(4):780-1. doi: 10.1136/ard.2009.111005

19. Zyulyaeva TP, Babaev MA, Eremenko AA, et al. Peculiarities of the course of the postoperative period in patients with coronary heart disease older than 70 years after operations of myocardial revascularization. Anesteziologiya i Reanimatologiya. 2013;(2):73-8 (In Russ.).

20. Михайлов ЕЕ, Беневоленская ЛИ. Руководство по остеопорозу. Москва: БИНОМ. Лаборатория знаний; 2003 [Mikhailov EE, Benevolenskaya LI. Rukovodstvo po osteoporozu [Guide to Osteoporosis]. Moscow: BINOM. Laboratoriya znanii; 2003 (In Russ.)].

21. Mohammad AJ, Englund M, Turesson C, et al. Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. J Rheumatol. 2017;44(1):84-90. doi: 10.3899/jrheum.160249

22. Udayakumar PD, Chandran AK, Crowson CS, et al. Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study. Arthritis Care Res (Hoboken). 2015;67(3):396-402. doi: 10.1002/acr.22416

23. Durand M, Thomas SL. Incidence of infections in patients with giant cell arteritis: a cohort study. Arthritis Care Res (Hoboken). 2012;64(4):581-8. doi: 10.1002/acr.21569

24. Schmidt J, Smail A, Roche B, et al. Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study. Arthritis Rheum. 2016;68(6):1477-82. doi: 10.1002/art.39596

25. Iwagaitsu S, Naniwa T. Improvement of Arterial Wall Lesions in Parallel with Decrease of Plasma Pentraxin-3 Levels in a Patient with Refractory Takayasu Arteritis after Treatment with Tocilizumab. Case Rep Rheumatol. 2017;2017:4580967. doi: 10.1155/2017/4580967

26. Lally L, Forbess L, Hatziz C, Spiera R. A prospective open-label phase IIA trial of tocilizumab in the treatment of polymyalgia rheumatic. Arthritis Rheum. 2016;68:2550-4. doi: 10.1002/art.39740

27. Vionnet J, Buss G, Mayer C, et al. Tocilizumab for giant cell arteritis with corticosteroid-resistant progressive anterior ischemic optic neuropathy. Joint Bone Spine. 2017;9. pii: S1297-319X(17)30091-X. doi: 10.1016/j.jbspin.2017.04.009

28. Regent A, Redeker S, Deroux A, et al. French Vasculitis Group, the Groupe Francais pour l'Etude de l'Arterite a Cellules Geantes, and the Club Rhumatismes et Inflammation. Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients. J Rheumatol. 2016;43:1547-52. doi: 10.3899/jrheum.151252

29. Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906-15. doi: 10.1161/CIRCULATIONAHA.109.872903.